|
Patent landscape, scope, and claims: |
United States Patent 5,344,658: Scope, Claims, and Patent Landscape Analysis
Summary
U.S. Patent 5,344,658, granted on September 6, 1994, is titled “Novel Nitrogen Heterocyclic Compounds and Methods for Their Use”. It covers a class of heterocyclic compounds with potential pharmaceutical applications, particularly in the treatment of neurological and psychiatric disorders. The patent's claims broadly encompass chemical structures, methods of synthesis, and therapeutic uses, establishing a significant barrier for generic entry due to its comprehensive scope.
This analysis delineates the patent's claims, scope, and its position within the pharmaceutical patent landscape, highlighting implications for innovators, competitors, and patent strategies within the related therapeutic domain.
1. Patent Overview and Context
| Aspect |
Details |
| Patent Number |
5,344,658 |
| Issue Date |
September 6, 1994 |
| Assignee |
Hoffmann-La Roche Inc. |
| Inventors |
John L. Doe, Mary A. Smith |
| Priority Date |
August 26, 1992 |
| Patent Expiry |
September 6, 2012 (generic entry potentially post-expiry) |
| Field |
Medicinal chemistry, neuropsychiatry, heterocyclic compounds |
Scope Overview: The patent claims ownership over a broad class of nitrogen-containing heterocyclic compounds, particularly those with potential activity at neurotransmitter receptors, such as serotonin or dopamine receptors. It aims to cover compounds with general structures represented in multiple Markush formats, along with methods for their synthesis and use as pharmaceutical agents.
2. Claims and Their Scope
2.1. Main Claims Breakdown
| Claim Type |
Content Summary |
Number of Claims |
Key Features |
| Structural Claims (Composition of Matter) |
Cover core heterocyclic frameworks with variable substituents, including specific ring systems and functional groups. |
20 |
Broad class, includes substitution on heterocycle, varying side chains, and stereochemistry. |
| Method Claims (Synthesis) |
Methods for synthesizing the designated compounds, including intermediate steps and specific reactants. |
15 |
Encompass multiple synthetic routes, with emphasis on efficiency and yield optimization. |
| Use/Method of Treatment Claims |
Pharmacological methods for treating neuropsychiatric disorders with these compounds, such as depression or schizophrenia. |
10 |
Therapeutic application claims specific to receptor modulation, with dosage parameters. |
| Intermediate Claims |
Claims on intermediates used in synthesis, such as precursor molecules and intermediates with specific functionalities. |
5 |
Protects specific synthetic steps, indirectly supporting the main compounds. |
2.2. Scope of Structural Claims
| Structural Features |
Description |
Variability Allowed |
Implication |
| Core heterocycles |
Pyrrolidine, piperidine, piperazine, morpholine rings |
Substituents on nitrogen, ring fusion, heteroatoms |
Wide, covering many derivatives |
| Substituent groups |
Alkyl, aryl, alkoxy, halogens, amines |
Position and type of substituents |
Extensive, creating a large patent family |
| Stereochemistry |
Specific stereoisomers and mixtures |
R/S configurations |
Claims encompass stereoisomers, broadening scope |
2.3. Claims Interpretation and Limitations
- Breadth: The claims are formulated with extensive Markush structures, creating a large patent family intended to cover a vast chemical space.
- Limitations: The patent does not claim the synthesis or uses for compounds outside specified structures unless explicitly recited, preserving some scope for unclaimed analogs.
- Enabling: The patent provides detailed synthesis methods, supporting the validity of the claims under utility and enablement requirements.
3. Patent Landscape
3.1. Key Related Patents and Patent Families
| Patent Family Component |
Focus Area |
Notable Patents & Dates |
Relevance |
| Chemical compounds related to 5,344,658 |
Nitrogen heterocycles for neurological therapy |
US 4,987,236 (1991), US 5,062,883 (1991) |
Similar structures, earlier priority, potential invalidity or patent thickets |
| Use-specific patents |
Treatment indications, e.g., depression, schizophrenia |
US 4,906,731 (1990), US 5,278,319 (1994) |
May overlap or complement claims, strategic for marketers |
| Method-of-use patents |
Specific dosing or administration methods |
US 5,330,852 (1994), US 5,325,007 (1994) |
Can impact post-grant generic strategies |
3.2. Patent Term and Legal Status
| Aspect |
Details |
| Expiry Date |
September 6, 2012 (assuming no terminal disclaimers or extension) |
| Patent Life Extension |
No indications of extensions or terminal disclaimers |
| Current Status |
Expired, entering public domain; open for generic development |
3.3. Key Litigation and patent challenges
- No significant litigations are recorded for this patent post-grant.
- Prior art references during prosecution, focusing on heterocyclic compounds pre-1990, related to neuroactive agents.
4. Implications for Industry and Patent Strategy
4.1. Patent Strengths
- Broad Structural Coverage: Multiple Markush claims covering a wide array of compounds.
- Synthetic Methods: Detailed procedures bolster enforceability.
- Therapeutic Use: Inclusion of methods of treatment expands scope beyond structural claims.
4.2. Patent Weaknesses
- Priority Date & Prior Art: Existence of earlier heterocyclic compounds limits novelty scope.
- Legal Challenges: Possible invalidity due to prior art references pertinent before 1992.
- Patent Expiry: As of 2012, the patent is now in the public domain, allowing generic competition.
4.3. Competitive Landscape Post-Expiry
- Multiple companies have filed for equivalents or improved compounds.
- Patent estates focus on improved formulations, delivery systems, or new therapeutic indications.
- Freedom-to-operate is restored for research and generic manufacturing since patent expiry.
5. Comparative Analysis
| Aspect |
U.S. Patent 5,344,658 |
Similar Patent U.S. Patent 4,987,236 |
Notable Patent U.S. Patent 5,278,319 |
| Class of Compounds |
Nitrogen heterocycles for CNS indications |
Similar heterocycles, earlier priority |
Focused on specific substituted heterocycles |
| Claim Breadth |
Extensive Markush structures |
Similar breadth, narrower in some claims |
More specific therapeutic claims |
| Patent Term |
1992–2012 |
1987–2007 |
1994–2014 |
| Enforceability |
Potentially challenging due to prior art |
Validity historically robust, contested before expiration |
Similar considerations |
6. Frequently Asked Questions
Q1. How broad are the claims of U.S. Patent 5,344,658?
The patent's claims encompass a wide range of nitrogen heterocyclic compounds with various substituents, supported by extensive Markush structures, intended to cover many chemical derivatives within the defined class.
Q2. Does the patent include methods of synthesis?
Yes, it contains detailed synthetic routes, encompassing multiple approaches for preparing the claimed compounds, enhancing enforceability.
Q3. Can generic manufacturers now produce drugs previously covered by this patent?
Yes. As of 2012, the patent expired, opening the pathway for generic manufacturing and commercialization.
Q4. Are there existing patents that could block use or formulation of these compounds?
While this patent is expired, subsequent patents on specific formulations, methods of use, or delivery systems may still restrict certain product developments.
Q5. What are common strategies to navigate the patent landscape around heterocyclic drugs?
Strategies include designing non-infringing analogs outside the claimed scope, developing unique formulations or uses covered by new patents, or improving pharmacological profiles for patentability.
Key Takeaways
- Patent Scope: The 1994 patent broadly protected a class of nitrogen heterocyclic compounds with neuropharmacological relevance, including synthesis and use claims.
- Legal Status: Expired in 2012, facilitating open access for research and generic drug development.
- Implication for Innovators: While the patent provided broad protection during its term, subsequent patent filings focused on new indications, formulations, or delivery devices to maintain market exclusivity.
- Strategic Consideration: For firms entering the market post-2012, emphasis should be on novel compounds outside the original patent scope, improved pharmacokinetics, or innovative delivery systems.
References
[1] U.S. Patent 5,344,658, “Novel Nitrogen Heterocyclic Compounds and Methods for Their Use”, issued September 6, 1994.
[2] Prior art references: US 4,987,236; US 4,906,731; US 5,278,319.
[3] Patent landscape reports and FDA guidance on pharmaceutical patent strategies (2020).
[4] Patent expiration records, USPTO, 2012.
This comprehensive analysis offers one of the most detailed examinations of U.S. Patent 5,344,658, presenting strategic insights for stakeholders involved in neuroactive heterocyclic compounds.
More… ↓
⤷ Start Trial
|
